Literature DB >> 14665612

Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

Lynn M Schuchter.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14665612     DOI: 10.1200/JCO.2004.10.907

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

Review 1.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

2.  Recent advances in sunlight-induced carcinogenesis using the Xiphophorus melanoma model.

Authors:  André A Fernandez; Lakshmi Paniker; Rachel Garcia; David L Mitchell
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2011-03-30       Impact factor: 3.228

3.  [Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma].

Authors:  E Richtig; G Langmann; G Schlemmer; K Müllner; G Papaefthymiou; P Bergthaler; J Smolle
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

4.  A multimarker prognostic assay for primary cutaneous melanoma.

Authors:  Mohammed Kashani-Sabet; Suraj Venna; Mehdi Nosrati; Javier Rangel; Antje Sucker; Friederike Egberts; Frederick L Baehner; Jeff Simko; Stanley P L Leong; Chris Haqq; Axel Hauschild; Dirk Schadendorf; James R Miller; Richard W Sagebiel
Journal:  Clin Cancer Res       Date:  2009-11-03       Impact factor: 12.531

5.  Antitumor immunity and cancer stem cells.

Authors:  Tobias Schatton; Markus H Frank
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

6.  Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations.

Authors:  C Lee Ventola
Journal:  P T       Date:  2017-07

7.  Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].

Authors:  Vanna Chiarion-Sileni; Paola Del Bianco; Antonella Romanini; Michele Guida; Adriano Paccagnella; Maurizio Dalla Palma; Emanuele Naglieri; Ruggero Ridolfi; Barbara Silvestri; Maria Michiara; Gian Luca De Salvo
Journal:  BMC Cancer       Date:  2006-02-27       Impact factor: 4.430

8.  Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy.

Authors:  E Lau; J Sedy; C Sander; M A Shaw; Y Feng; M Scortegagna; G Claps; S Robinson; P Cheng; R Srivas; S Soonthornvacharin; T Ideker; M Bosenberg; R Gonzalez; W Robinson; S K Chanda; C Ware; R Dummer; D Hoon; J M Kirkwood; Z A Ronai
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

9.  Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.

Authors:  Peter Mohr; Felix Kiecker; Virtudes Soriano; Olivier Dereure; Karmele Mujika; Philippe Saiag; Jochen Utikal; Rama Koneru; Caroline Robert; Florencia Cuadros; Matias Chacón; Rodrigo U Villarroel; Yana G Najjar; Lisa Kottschade; Eva M Couselo; Roy Koruth; Annie Guérin; Rebecca Burne; Raluca Ionescu-Ittu; Maurice Perrinjaquet; Jonathan S Zager
Journal:  Melanoma Manag       Date:  2019-10-04

10.  Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

Authors:  A Hauschild
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.